This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q83880687
rdf:type
wikibase:Item
schema:description
article scientifique publié en 2011 artículu científicu espublizáu n'abril de 2011 scientific article published on 15 April 2011 wetenschappelijk artikel наукова стаття, опублікована у квітні 2011
p:P577
wds:Q83880687-31599CA8-63CB-4D8D-A42B-2275904C4B1A
wdt:P577
2011-04-15T00:00:00Z
p:P2093
wds:Q83880687-7FAF421A-3071-437D-80C0-92BB84CE8AE5 wds:Q83880687-F67884BA-3AE4-4A3D-AA9E-6BCDFD759F21
wdt:P2093
Cedric Delhaye Manuel A Gonzalez
rdfs:label
Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents
skos:prefLabel
Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents
schema:name
Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents
p:P50
wds:Q83880687-2E2DA54E-4BA4-404A-9AEE-E525B2152D9F wds:Q83880687-307053DB-9B90-40D5-B846-97F89F29602B wds:Q83880687-44359334-2540-4183-A8EB-B80601A7B9F9 wds:Q83880687-49375D0B-EC61-43AB-BA61-C5A3F99C87A5 wds:Q83880687-CF769C0C-DFBD-4638-8362-EF35B08E494C wds:Q83880687-E33CD018-71A5-432C-90D9-6128C2C5DADD wds:Q83880687-E6E119A1-7B89-47A6-9EB0-E67DE2B4B39A wds:Q83880687-FA744B6A-F27B-4996-95A3-1FEA35840C2E wds:Q83880687-67661B4E-F5EE-4089-A1BF-5C45676A8852 wds:Q83880687-6A75F829-D33F-4C29-8104-D2CF15E4481E wds:Q83880687-77B7BEDF-7818-41BE-889F-D0813AD7CE86 wds:Q83880687-77E67677-3523-4198-8BC1-065C641294B7
wdt:P50
wd:Q88227547 wd:Q88840517 wd:Q114406227 wd:Q7364511 wd:Q106695575 wd:Q106695580 wd:Q114406231 wd:Q106695518 wd:Q114406229 wd:Q57694514 wd:Q63919079 wd:Q106695449
p:P1476
wds:Q83880687-5916EF5D-785B-4BB2-A321-585E02B825F1
wdt:P1476
Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents
p:P304
wds:Q83880687-BB7709CA-8C85-413B-B982-5C24B03DA4B8
wdt:P304
1757-1762
p:P31
wds:Q83880687-0A662F85-4FDE-4F62-BDA9-EEC2B1B52BFE
wdt:P31
wd:Q13442814
p:P698
wds:Q83880687-584D5B74-3593-4493-A2BA-3EED5703A1A3
wdtn:P698
n12:21497782
wdt:P698
21497782
p:P1433
wds:Q83880687-CDCDBA69-1722-427A-8673-ACD5C5B8EC43
wdt:P1433
wd:Q2208417
p:P433
wds:Q83880687-30AEA30E-6C8B-4A47-B43D-55A662AC9CE8
p:P478
wds:Q83880687-BC298947-1F7D-4F5B-8C9E-DE1A8D9E576D
wdt:P433
12
wdt:P478
107
p:P356
wds:Q83880687-AAB868FC-F31C-45C8-80E5-BD9E99B15B95
wdtn:P356
n11:J.AMJCARD.2011.02.330
wdt:P356
10.1016/J.AMJCARD.2011.02.330